BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 25316820)

  • 21. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
    Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
    Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14.
    Francisco JA; Donaldson KL; Chace D; Siegall CB; Wahl AF
    Cancer Res; 2000 Jun; 60(12):3225-31. PubMed ID: 10866315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer.
    Garris CS; Wong JL; Ravetch JV; Knorr DA
    Sci Transl Med; 2021 May; 13(594):. PubMed ID: 34011627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of agonistic anti-CD40 therapy in treatments for cancer.
    Khong A; Nelson DJ; Nowak AK; Lake RA; Robinson BW
    Int Rev Immunol; 2012 Aug; 31(4):246-66. PubMed ID: 22804570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.
    Saha A; Chatterjee SK; Foon KA; Primus FJ; Sreedharan S; Mohanty K; Bhattacharya-Chatterjee M
    Cancer Res; 2004 Jul; 64(14):4995-5003. PubMed ID: 15256474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.
    Gonzalez-Carmona MA; Lukacs-Kornek V; Timmerman A; Shabani S; Kornek M; Vogt A; Yildiz Y; Sievers E; Schmidt-Wolf IG; Caselmann WH; Sauerbruch T; Schmitz V
    Hepatology; 2008 Jul; 48(1):157-68. PubMed ID: 18537185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCMab1, a monoclonal antibody against aberrantly glycosylated integrin α3β1, has potent antitumor activity of bladder cancer in vivo.
    Li C; Yang Z; Du Y; Tang H; Chen J; Hu D; Fan Z
    Clin Cancer Res; 2014 Aug; 20(15):4001-13. PubMed ID: 25002124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
    Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
    Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity.
    Balkow S; Loser K; Krummen M; Higuchi T; Rothoeft T; Apelt J; Tuettenberg A; Weishaupt C; Beissert S; Grabbe S
    Exp Dermatol; 2009 Jan; 18(1):78-87. PubMed ID: 19054060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.
    Zhou J; Chen J; Zhong R; Mokotoff M; Shultz LD; Ball ED
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2224-31. PubMed ID: 16609038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity.
    Ishihara J; Ishihara A; Potin L; Hosseinchi P; Fukunaga K; Damo M; Gajewski TF; Swartz MA; Hubbell JA
    Mol Cancer Ther; 2018 Nov; 17(11):2399-2411. PubMed ID: 30097487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
    Ren Z; Guo J; Liao J; Luan Y; Liu Z; Sun Z; Liu X; Liang Y; Peng H; Fu YX
    Clin Cancer Res; 2017 Jan; 23(1):193-203. PubMed ID: 27354469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human dendritic cells activate T lymphocytes via a CD40: CD40 ligand-dependent pathway.
    McLellan AD; Sorg RV; Williams LA; Hart DN
    Eur J Immunol; 1996 Jun; 26(6):1204-10. PubMed ID: 8647193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
    Richman LP; Vonderheide RH
    Cancer Immunol Res; 2014 Jan; 2(1):19-26. PubMed ID: 24416732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor immunity against bladder cancer induced by ex vivo expression of CD40 ligand gene using retrovirus vector.
    Kimura T; Ohashi T; Kikuchi T; Kiyota H; Eto Y; Ohishi Y
    Cancer Gene Ther; 2003 Nov; 10(11):833-9. PubMed ID: 14605669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer.
    Zhang P; Wang J; Wang D; Wang H; Shan F; Chen L; Hou Y; Wang E; Lu CL
    Int Immunopharmacol; 2012 Nov; 14(3):252-60. PubMed ID: 22884511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
    J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transglutaminase 2 on the surface of dendritic cells is proposed to be involved in dendritic cell-T cell interaction.
    Kim JH; Jeong EM; Jeong YJ; Lee WJ; Kang JS; Kim IG; Hwang YI
    Cell Immunol; 2014; 289(1-2):55-62. PubMed ID: 24727157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects.
    Welniak LA; Shorts L; Subleski J; Blazar BR; Wiltrout RH; Murphy WJ
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):534-9. PubMed ID: 15282531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies.
    Evans EE; Jonason AS; Bussler H; Torno S; Veeraraghavan J; Reilly C; Doherty MA; Seils J; Winter LA; Mallow C; Kirk R; Howell A; Giralico S; Scrivens M; Klimatcheva K; Fisher TL; Bowers WJ; Paris M; Smith ES; Zauderer M
    Cancer Immunol Res; 2015 Jun; 3(6):689-701. PubMed ID: 25614511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.